Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$27.3M
36M shares
52-week range
$0.63 – $2.19
5% from low
Exchange
NASDAQ
CS
Borrow rate
5.16%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $89.0K | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | −$89.0K | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $898.0K | $2.5M | $3.1M | $6.4M | $7.3M | $5.7M | $6.2M |
| Operating income | −$1.2M | −$2.9M | −$5.6M | −$13.6M | −$12.0M | −$9.9M | −$11.1M |
| EBITDA | −$1.3M | −$2.8M | −$2.9M | −$12.2M | −$9.6M | −$9.9M | −$11.1M |
| Net income | −$1.2M | −$2.8M | −$4.0M | −$12.3M | −$10.1M | −$10.2M | −$11.1M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.22 | -0.51 | -0.23 | -1.07 | -0.83 | -0.55 | -0.44 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $714067 | $-0.39 | $-0.39–$-0.37 | 1 |
| 2027 | $3M | $-0.82 | $-0.82–$-0.82 | 1 |
| 2028 | $13M | $-0.26 | $-0.26–$-0.26 | 1 |
| 2029 | $360M | $1.65 | $1.65–$1.65 | 1 |
Forward consensus · source: Financial Modeling Prep
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
www.neurosense-tx.comNo one on the platform currently holds NRSN.
No tracked institution reports a position in NRSN as of their last filing.
No one on the platform has traded NRSN yet.
| -7.10% |
| $20M |
| — |
| NERVMinerva Neurosciences, Inc. | $5.43 | +24.26% | $38M | — |
| NRXSNeurAxis, Inc. | $7.14 | -1.79% | $88M | — |
Source: Financial Modeling Prep · peers by sector/industry
$NRSN They are desperate for cash, so every good news that raises the stock price, even just by a dime or two is nearly always accompanied by their ATM sales to generate cash to keep the lights on. A grant could help bridge the gap until they can finally secure a partnership to fund Phase3. I hope they have applied for grants months ago because it takes months to receive a response.
View on StockTwits ↗$NRSN Every good news this shit drops ! Give us some bad news ! 🤣😂
View on StockTwits ↗@black_ambition see $AMLX story from 2021 very similar to $NRSN reached a $3 billion valuation so a buyout early could be $1.5 billion but successful implementation of phase 3, and add additional alzheimers trials with similar results looking at $7 billion+ talking 3+ years for that.
View on StockTwits ↗$NRSN How many shares available for shorts ? Fintel not updated !!
View on StockTwits ↗$NRSN Wake me up when the ATM is done. Fundamentals keep getting stronger, and I’ll happily add more. 😂
View on StockTwits ↗$NRSN Whether today's news is strong enough to finally convert partner interest into a signed deal, and whether it is strong enough for Health Canada to move toward with a positive NOC/c determination, remains to be seen. But the scientific foundation of both those conversations changed significantly
View on StockTwits ↗$NRSN It upsets everyone that someone manages to bring us all down. If we all unite, we can prevent him from harming us.
View on StockTwits ↗$NRSN Today from 0.95 to 0.69 … bullshit !! 🤬🤬🤬 we almost got $1 in premarket ! You fuckin kidding me ?!!!
View on StockTwits ↗$NRSN They are forcibly lowering the rate in small increments of 100 So that they don't feel that it's him. Sell and buy immediately. Now lock the rate at 0.69. A short position has been opened and they are working to forcefully lower the rate. Together we will prevent this scheme.
View on StockTwits ↗$NRSN So I finally got around to watching the EverythingALS video. My sense is that they’re waiting for the Canadian NOC to provide feedback or action items rather than simply accepting accelerated approval. If that’s the case, the delay in enrollment makes some sense. It would also give them a chance to make minor adjustments to the Phase 3 trial based on that feedback, and it could give a potential partner more clarity on how much funding to commit. If there truly a partner behind this, they would need to know those meeting minutes. They still have not replaced their Chief Scientific Officer who was let go in April I also came away thinking that Alon may be preparing to sell the program. He seemed much less promotional, more relaxed and straightforward (even though inconclusive) than in previous interviews and more focused on simply explaining the current situation.
View on StockTwits ↗$NRSN This small biotech just became the first company ever to clinically reduce TDP-43 (the defining hallmark of ALS) in a controlled trial. The director of Harvard's ALS center called it compelling and endorsed Phase 3. The drug works. Now they need to find the money to prove it at scale.
View on StockTwits ↗$NRSN They are forcibly lowering the rate in small increments of 100 So that they don't feel that it's him. Sell and buy immediately. Now lock the rate at 0.70. A short position has been opened and they are working to forcefully lower the rate. Together we will prevent this scheme.
View on StockTwits ↗$NRSN So if there is a partner, who this partner gonna be ? To make this a big uptrend ?!!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.